Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation

被引:9
|
作者
Thompson, Molly H. [1 ]
Wilson, Sylvia H. [2 ]
Toussaint, Brittany L. [1 ]
Jordan, Cameron L. [1 ]
Hayes, Genevieve L. [1 ]
McKinzie, Brian P. [1 ]
Wolf, Bethany J. [3 ]
Field, Larry C. [2 ]
机构
[1] Med Univ South Carolina, Dept Pharm Serv, 150 Ashley Ave,MSC 584, Charleston, SC 29425 USA
[2] Med Univ South Carolina, Dept Anesthesia & Perioperat Med, 167 Ashley Ave,Suite 301,MSC 912, Charleston, SC 29425 USA
[3] Med Univ South Carolina, Dept Publ Hlth Sci, 135 Cannon St,Suite 303,MSC 835, Charleston, SC 29425 USA
关键词
Unfractionated heparin; Venous thromboembolism prophylaxis; Activated partial thromboplastin time; DEEP-VEIN THROMBOSIS; NEURAXIAL ANESTHESIA; PULMONARY-EMBOLISM; VENOUS THROMBOSIS; ANALGESIA; OBESITY; TRIALS;
D O I
10.1016/j.jclinane.2015.11.020
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Study Objective: Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). Design: Retrospective, cohort analysis. Setting: Single-center, university hospital. Measurements: Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. Main Results: Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean +/- SD, 32.0 +/- 8.5 seconds). After initiation of UFH, aPTT values increased (mean SD, 37.6 +/- 15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean SD, 38.6 +/- 15.5) exceeded the normal laboratory range (23.3-35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. Conclusions: Treatment with UFH resulted in a small, but significant, increase in aPTT. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:346 / 350
页数:5
相关论文
共 50 条
  • [1] Varying Dosages of Subcutaneous Unfractionated Heparin and Activated Partial Thromboplastin Time in Hospitalized Antepartum Patients: A Retrospective Cohort Analysis
    Elmofty, Dalia H.
    Tucker, Andrew
    Wuenstel, Andrew M.
    Cheng, Paul K.
    Fox, Edward
    Knoebel, Randall
    Liao, Chuanghong
    Scavone, Barbara
    ANESTHESIA AND ANALGESIA, 2022, 134 (05): : 1028 - 1034
  • [2] Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin
    Gouin-Thibault, Isabelle
    Samama, Michel M.
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (05) : 986 - 987
  • [3] Stability of the activated partial thromboplastin time used to monitor unfractionated heparin
    Ray, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (10) : 1817 - 1819
  • [4] EFFECT OF HEPARIN ON ACTIVATED PARTIAL THROMBOPLASTIN TIME
    TRIPLETT, DA
    HARMS, CS
    KOEPKE, JA
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1978, 70 (03) : 556 - 559
  • [5] Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges
    van den Besselaar, AMHP
    Sturk, A
    Reijnierse, GLA
    THROMBOSIS RESEARCH, 2002, 107 (05) : 235 - 240
  • [6] Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations
    Marlar, Richard A.
    Clement, Bernadette
    Gausman, Jana
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2017, 43 (03): : 253 - 260
  • [7] Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin
    Vandiver, Jeremy W.
    Vondracek, Thomas G.
    PHARMACOTHERAPY, 2012, 32 (06): : 546 - 558
  • [8] Activated Partial Thromboplastin Time Elevation After Low-Dose Unfractionated Heparin
    Pirouz, R.
    Smith, P. R.
    Vaynkof, Y.
    Balakrishna, S.
    Chand, R.
    Atluri, S.
    Gerolemou, L.
    Elias, M.
    Mir, S.
    Nishimoto, T.
    Surapaneni, P.
    Jimenez, E.
    O'Neill, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [9] Monitoring Unfractionated Heparin: A Review of Activated Partial Thromboplastin Time Versus Antifactor Xa
    Parker, Christine R.
    Kataria, Vivek
    AACN ADVANCED CRITICAL CARE, 2019, 30 (04) : 305 - 312
  • [10] The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy
    Lapic, Ivana
    Vrancic, Ana Loncar
    Herak, Desiree Coen
    Rogic, Dunja
    BIOCHEMIA MEDICA, 2021, 31 (02) : 021003